Research group:

Demyelinating Disease

Dr Marzena Fabis-Pedrini

MSc, PhD MSWA MS Research Coordinator/Research Fellow

Dr Marzena Fabis-Pedrini is an MSWA Research Fellow in the area of Demyelinating Diseases. Previously she worked as a Postdoctoral Research Fellow and then as a Research Instructor at Thomas Jefferson University in Philadelphia, USA. In 2012 she moved to Australia and started clinical research in ANRI renamed later as WANRI and recently known as Perron Institute for Neurological and Translational Science.

Multiple sclerosis (MS) is Dr Fabis-Pedrini’s key focus. She is dedicated to investigating the causes of MS and improving the treatment and management of those suffering from MS and related diseases.
The focus of her work is on several research projects including the investigation of the clinical profile of different subgroups of patients with demyelinating diseases in Western Australia and, the influence of HLA alleles and haplotypes on disease susceptibility and clinical and laboratory characteristics.

In January 2015, Dr Fabis-Pedrini in collaboration with Clinical Professor Allan Kermode and Nobel Laureate, Professor Barry J Marshall AC, revealed that prior infection with the ‘stomach ulcer bug’ H. pylori is associated with a lower risk of developing MS. This was published in the Journal of Neurology, Neurosurgery and Psychiatry.

Find Dr Fabis-Pedrini on ORCID

Publications

Bukhari W., Khalilidehkordi E., Mason D.F., Barnett M.H., Taylor B.V., Fabis-Pedrini M., Kermode A.G., Subramanian S., Waters P., Broadley S.A., Bukhari W., Broadley S.A., Abernethy D., Bhuta S., Blum S., Boggild M., Boundy K., Brew B.J., Brilot F., Brownlee W.J., Bundell C.S., Butzkueven H., Carroll W.M., Chen C., Clarke L., Coulthard A., Dale R.C., Das C., Dear K., Fulcher D., Gillis D., Hawke S., Heard R., Henderson A.P.D., Heshmat S., Hodgkinson S., Jimenez Sanchez S., Kilpatrick T.J., King J., Kneebone C., Kornberg A.J., Lechner-Scott J., Lin M.-W., Lynch C., Macdonell R.A.L., Marriott M.P., McCombe P.A., O’Gorman C., Parratt J.D.E., Pender M.P., Pereira J., Pollard J.D., Prain K.M., Ramanathan S., Reddell S.W., Shaw C., Silvestrini R.A., Slee M., Spies J., Stankovich J., Sutton I., Vincent A., Vucic S., Walsh M., Willoughby E., Wong R.C., Woodhall M., Yiu E.M., The Australian and New Zealand NMO Collaboration
NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand (2021)
Journal of Neurology DOI: 10.1007/s00415-021-10665-9
Clarke L., Arnett S., Bukhari W., Khalilidehkordi E., Jimenez Sanchez S., O'Gorman C., Sun J., Prain K.M., Woodhall M., Silvestrini R., Bundell C.S., Abernethy D.A., Bhuta S., Blum S., Boggild M., Boundy K., Brew B.J., Brownlee W., Butzkueven H., Carroll W.M., Chen C., Coulthard A., Dale R.C., Das C., Fabis-Pedrini M.J., Gillis D., Hawke S., Heard R., Henderson A.P.D., Heshmat S., Hodgkinson S., Kilpatrick T.J., King J., Kneebone C., Kornberg A.J., Lechner-Scott J., Lin M.-W., Lynch C., Macdonell R.A.L., Mason D.F., McCombe P.A., Pereira J., Pollard J.D., Ramanathan S., Reddel S.W., Shaw C.P., Spies J.M., Stankovich J., Sutton I., Vucic S., Walsh M., Wong R.C., Yiu E.M., Barnett M.H., Kermode A.G.K., Marriott M.P., Parratt J.D.E., Slee M., Taylor B.V., Willoughby E., Brilot F., Vincent A., Waters P., Broadley S.A.
MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis (2021)
Frontiers in Neurology. 12 DOI: 10.3389/fneur.2021.722237
Bukhari W., Clarke L., O’Gorman C., Khalilidehkordi E., Arnett S., Prain K.M., Woodhall M., Silvestrini R., Bundell C.S., Ramanathan S., Abernethy D., Bhuta S., Blum S., Boggild M., Boundy K., Brew B.J., Brownlee W., Butzkueven H., Carroll W.M., Chen C., Coulthard A., Dale R.C., Das C., Dear K., Fabis-Pedrini M.J., Fulcher D., Gillis D., Hawke S., Heard R., Henderson A.P.D., Heshmat S., Hodgkinson S., Jimenez-Sanchez S., Kilpatrick T.J., King J., Kneebone C., Kornberg A.J., Lechner-Scott J., Lin M.-W., Lynch C., Macdonnell R.A.L., Mason D.F., McCombe P.A., Pereira J., Pollard J.D., Reddel S.W., Shaw C., Spies J., Stankovich J., Sutton I., Vucic S., Walsh M., Wong R.C., Yiu E.M., Barnett M.H., Kermode A.G., Marriott M.P., Parratt J., Slee M., Taylor B.V., Willoughby E., Wilson R.J., Brilot F., Vincent A., Waters P., Broadley S.A.
The clinical profile of NMOSD in Australia and New Zealand (2020)
Journal of Neurology. 267(5):1431-1443. DOI: 10.1007/s00415-020-09716-4
Khalilidehkordi E., Clarke L., Arnett S., Bukhari W., Jimenez Sanchez S., O'Gorman C., Sun J., Prain K.M., Woodhall M., Silvestrini R., Bundell C.S., Abernethy D., Bhuta S., Blum S., Boggild M., Boundy K., Brew B.J., Brown M., Brownlee W., Butzkueven H., Carroll W.M., Chen C., Coulthard A., Dale R.C., Das C., Fabis-Pedrini M.J., Fulcher D., Gillis D., Hawke S., Heard R., Henderson A.P.D., Heshmat S., Hodgkinson S., Kilpatrick T.J., King J., Kneebone C., Kornberg A.J., Lechner-Scott J., Lin M.-W., Lynch C., Macdonell R.A.L., Mason D.F., McCombe P.A., Pereira J., Pollard J.D., Ramanathan S., Reddel S.W., Shaw C., Spies J., Stankovich J., Sutton I., Vucic S., Walsh M., Wong R.C., Yiu E.M., Barnett M.H., Kermode A.G., Marriott M.P., Parratt J., Slee M., Taylor B.V., Willoughby E., Brilot F., Vincent A., Waters P., Broadley S.A.
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation (2020)
Frontiers in Neurology. 11 DOI: 10.3389/fneur.2020.00537
Trend S., Jones A.P., Cha L., Cooper M.N., Geldenhuys S., Fabis-Pedrini M.J., Carroll W.M., Cole J.M., Booth D.R., Lucas R.M., French M.A., Byrne S.N., Kermode A.G., Hart P.H.
Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome (2019)
Scientific Reports. 9(1) DOI: 10.1038/s41598-019-44488-6
Cha L., Jones A.P., Trend S., Byrne S.N., Fabis-Pedrini M.J., Carroll W.M., Lucas R.M., Cole J.M., Booth D.R., Kermode A.G., Hart P.H.
Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis (2018)
Clinical and Translational Immunology. 7(8) DOI: 10.1002/cti2.1037
Hart P.H., Jones A.P., Trend S., Cha L., Fabis-Pedrini M.J., Cooper M.N., d’Este C., Geldenhuys S., Carroll W.M., Byrne S.N., Booth D.R., Cole J.M., Lucas R.M., Kermode A.G.
A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study (2018)
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 4(2) DOI: 10.1177/2055217318773112
Fabis-Pedrini M.J., James I., Seewann A., Yau W.Y., van de Bovenkamp A.A., Sanders F.R.K., Qiu W., Burton J., Mastaglia F.L., Carroll W.M., Kermode A.G.
Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort (2018)
Journal of the Neurological Sciences. 388:12-18. DOI: 10.1016/j.jns.2018.02.036
Trend S., Jones A.P., Cha L., Byrne S.N., Geldenhuys S., Fabis-Pedrini M.J., Carroll W.M., Cole J.M., Booth D.R., Lucas R.M., Kermode A.G., French M.A., Hart P.H.
Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with clinically isolated syndrome (2018)
Frontiers in Immunology. 9(JUL) DOI: 10.3389/fimmu.2018.01590
Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Lechner-Scott J., Lugaresi A., Prat A., Girard M., Duquette P., Grammond P., Solaro C., Grand’Maison F., Hupperts R., Prevost J., Sola P., Ferraro D., Terzi M., Butler E., Slee M., Kermode A., Fabis-Pedrini M., McCombe P., Barnett M., Shaw C., Hodgkinson S., Butzkueven H., on behalf of the MSBase Study Group
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (2018)
Multiple Sclerosis Journal. 24(12):1617-1626. DOI: 10.1177/1352458517728812
Fabis-Pedrini M.J., Bundell C., Wee C.-K., Lucas M., McLean-Tooke A., Mastaglia F.L., Carroll W.M., Kermode A.G.
Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia (2018)
Journal of Neuroimmunology. 324:76-80. DOI: 10.1016/j.jneuroim.2018.09.006
Yau W.Y., Fabis-Pedrini M.J., Kermode A.G.
Fabry heterozygote mimicking multiple sclerosis (2017)
BMJ Case Reports. 2017 DOI: 10.1136/bcr-2017-220274
Cull G., Hall D., Fabis-Pedrini M.J., Carroll W.M., Forster L., Robins F., Ghassemifar R., Crosbie C., Walters S., James I., Augustson B., Kermode A.K.
Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS (2017)
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 3(1) DOI: 10.1177/2055217317700167
Fewings N.L., Gatt P.N., McKay F.C., Parnell G.P., Schibeci S.D., Edwards J., Basuki M.A., Goldinger A., Fabis-Pedrini M.J., Kermode A.G., Manrique C.P., McCauley J.L., Nickles D., Baranzini S.E., Burke T., Vucic S., Stewart G.J., Booth D.R.
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis (2017)
Journal of Autoimmunity. 78:57-69. DOI: 10.1016/j.jaut.2016.12.006
Fewings N., Gatt P.N., McKay F.C., Parnell G.P., Schibeci S.D., Edwards J., Basuki M.A., Goldinger A., Fabis-Pedrini M.J., Kermode A.G., Manrique C.P., McCauley J.L., Nickles D., Baranzini S.E., Burke T., Vucic S., Stewart G.J., Booth D.R.
Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis (2017)
Data in Brief. 11:364-370. DOI: 10.1016/j.dib.2017.02.040
Trend S., Jones A.P., Geldenhuys S., Byrne S.N., Fabis-Pedrini M.J., Nolan D., Booth D.R., Carroll W.M., Lucas R.M., Kermode A.G., Hart P.H.
Evolving identification of blood cells associated with clinically isolated syndrome: Importance of time since clinical presentation and diagnostic MRI (2017)
International Journal of Molecular Sciences. 18(6) DOI: 10.3390/ijms18061277
Mahurkar S., Moldovan M., Suppiah V., Sorosina M., Clarelli F., Liberatore G., Malhotra S., Montalban X., Antigüedad A., Krupa M., Jokubaitis V.G., McKay F.C., Gatt P.N., Fabis-Pedrini M.J., Martinelli V., Comi G., Lechner-Scott J., Kermode A.G., Slee M., Taylor B.V., Vandenbroeck K., Comabella M., Boneschi F.M., King C.
Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study (2017)
Pharmacogenomics Journal. 17(4):312-318. DOI: 10.1038/tpj.2016.20
Bukhari W., Prain K.M., Waters P., Woodhall M., O'Gorman C.M., Clarke L., Silvestrini R.A., Bundell C.S., Abernethy D., Bhuta S., Blum S., Boggild M., Boundy K., Brew B.J., Brown M., Brownlee W.J., Butzkueven H., Carroll W.M., Chen C., Coulthard A., Dale R.C., Das C., Dear K., Fabis-Pedrini M.J., Fulcher D., Gillis D., Hawke S., Heard R., Henderson A.P.D., Heshmat S., Hodgkinson S., Jimenez-Sanchez S., Killpatrick T., King J., Kneebone C., Kornberg A.J., Lechner-Scott J., Lin M.-W., Lynch C., Macdonell R., Mason D.F., McCombe P.A., Pender M.P., Pereira J.A., Pollard J.D., Reddel S.W., Shaw C., Spies J., Stankovich J., Sutton I., Vucic S., Walsh M., Wong R.C., Yiu E.M., Barnett M.H., Kermode A.G., Marriott M.P., Parratt J.D.E., Slee M., Taylor B.V., Willoughby E., Wilson R.J., Vincent A., Broadley S.A.
Incidence and prevalence of NMOSD in Australia and New Zealand (2017)
Journal of Neurology, Neurosurgery and Psychiatry. 88(8):632-638. DOI: 10.1136/jnnp-2016-314839
McKay F.C., Gatt P.N., Fewings N., Parnell G.P., Schibeci S.D., Basuki M.A.I., Powell J.E., Goldinger A., Fabis-Pedrini M.J., Kermode A.G., Burke T., Vucic S., Stewart G.J., Booth D.R.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies (2016)
Clinical Immunology. 163:96-107. DOI: 10.1016/j.clim.2015.12.015
Fabis-Pedrini M.J., Xu W., Burton J., Carroll W.M., Kermode A.G.
Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment (2016)
Journal of Clinical Neuroscience. 25:145-147. DOI: 10.1016/j.jocn.2015.08.027
Binder M.D., Fox A.D., Merlo D., Johnson L.J., Giuffrida L., Calvert S.E., Akkermann R., Ma G.Z.M., ANZgene, Perera A.A., Gresle M.M., Laverick L., Foo G., Fabis-Pedrini M.J., Spelman T., Jordan M.A., Baxter A.G., Foote S., Butzkueven H., Kilpatrick T.J., Field J., Kermode A.G., Taylor B., Booth D.R., Mason D., Stewart G.J., Charlesworth J., Wiley J., Lechner-Scott J., Tajouri L., Griffiths L., Slee M., Brown M.A., Moscato P., Scott R.J., Broadley S., Vucic S., MCarroll W.
Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status (2016)
PLoS Genetics. 12(3) DOI: 10.1371/journal.pgen.1005853
Yau W.Y., Fabis-Pedrini M.J., Kermode A.G.
Acute reversible seronegative cerebellar ataxia in a young woman with ovarian teratoma (2016)
Journal of the Neurological Sciences. 369:227-228. DOI: 10.1016/j.jns.2016.08.033
Pedrini M.J.F., Seewann A., Bennett K.A., Wood A.J.T., James I., Burton J., Marshall B.J., Carroll W.M., Kermode A.G.
Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females (2015)
Journal of Neurology, Neurosurgery and Psychiatry. 86(6):603-607. DOI: 10.1136/jnnp-2014-309759

Latest news

Keep informed with our latest updates.

View all news

Dr Marzena Fabis-Pedrini

Publications

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand (2021)

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis (2021)

The clinical profile of NMOSD in Australia and New Zealand (2020)

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation (2020)

Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome (2019)

Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis (2018)

A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study (2018)

Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort (2018)

Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with clinically isolated syndrome (2018)

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (2018)

Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia (2018)

Fabry heterozygote mimicking multiple sclerosis (2017)

Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS (2017)

The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis (2017)

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis (2017)

Evolving identification of blood cells associated with clinically isolated syndrome: Importance of time since clinical presentation and diagnostic MRI (2017)

Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study (2017)

Incidence and prevalence of NMOSD in Australia and New Zealand (2017)

The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies (2016)

Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment (2016)

Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status (2016)

Acute reversible seronegative cerebellar ataxia in a young woman with ovarian teratoma (2016)

Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females (2015)

Latest news

WA developed drug candidate may help treat Alzheimer’s

Perron Institute scientist’s own battle with anorexia nervosa drives her to find a cure – The West Australian

Publications

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand (2021)

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis (2021)

The clinical profile of NMOSD in Australia and New Zealand (2020)

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation (2020)

Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome (2019)

Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis (2018)

A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study (2018)

Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort (2018)

Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with clinically isolated syndrome (2018)

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (2018)

Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia (2018)

Fabry heterozygote mimicking multiple sclerosis (2017)

Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS (2017)

The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis (2017)

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis (2017)

Evolving identification of blood cells associated with clinically isolated syndrome: Importance of time since clinical presentation and diagnostic MRI (2017)

Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study (2017)

Incidence and prevalence of NMOSD in Australia and New Zealand (2017)

The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies (2016)

Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment (2016)

Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status (2016)

Acute reversible seronegative cerebellar ataxia in a young woman with ovarian teratoma (2016)

Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females (2015)

Latest news

Subscribe